Georgia's Online Cancer Information Center

Bladder Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Bladder Cancer
Cancer Type = Bladder Cancer
There are currently 19 active Bladder Cancer clinical trials in Georgia.
1.
9-ING-41 in Patients With Advanced Cancers
Cancer Type
Bladder Cancer, Bone Tumor, Brain & Spinal Cord Tumor, Breast Cancer, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCT ID
NCT03678883
Protocol IDs
1801
NCI-2018-03166
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
Cancer Type
Bile Duct Cancer, Bladder Cancer, Cervical Cancer, Colon/Rectal Cancer, Gallbladder Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT05086692
Protocol IDs
MDNA11-01
NCI-2022-02678
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04658862
Protocol IDs
CR108917
NCI-2021-10015
17000139BLC3001
2020-002620-36
7.
Afatinib Dimaleate in Treating Patients with Advanced Refractory Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary, Urethral Cancer
NCT ID
NCT02122172
Protocol IDs
IRB13-0540
NCI-2014-00859
13-0540
8.
Blue Light Cystoscopy With Cysview® Registry
Cancer Type
Bladder Cancer
NCT ID
NCT02660645
Protocol IDs
BLCCR-001
NCI-2018-00299
9.
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04878029
Protocol IDs
WINSHIP5259-21
NCI-2021-01365
STUDY00002329
10.
Chemoradiotherapy with or without Atezolizumab in Treating Patients with Localized Muscle Invasive Bladder Cancer
Cancer Type
Bladder Cancer
NCT ID
NCT03775265
Protocol IDs
S1806
S1806
NCI-2018-03264
Treatment Sites (1)
Southern Regional Medical Center
Riverdale
Stephen Cohen, MD
770-997-1975
11.
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer, CISTO Study
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT03933826
Protocol IDs
RG1121143
NCI-2020-06082
14.
Nivolumab and Ipilimumab in Treating Patients with Advanced Rare Genitourinary Tumors
Cancer Type
Adrenal Cancer, Bladder Cancer, Neuroendocrine Tumor, Penile Cancer, Prostate Cancer , Unknown Primary
NCT ID
NCT03333616
Protocol IDs
17-423
NCI-2018-00182
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
15.
NCORP Trial
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type
Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain Tumor, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Mesothelioma, Neuroendocrine Tumor, Ovarian Cancer, Parathyroid Cancer, Penile Cancer, Retroperitoneal Tumors, Sarcoma, Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT02834013
Protocol IDs
S1609
NCI-2016-01041
Treatment Sites (10)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Piedmont Fayette Hospital
Fayetteville
404-851-2340
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
17.
Propranolol Hydrochloride and Pembrolizumab for the Treatment of Recurrent or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCT ID
NCT04848519
Protocol IDs
WINSHIP5200-20
NCI-2021-00437
18.
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04452591
Protocol IDs
CG3002S
NCI-2021-01691
19.
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type
Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer
NCT ID
NCT03866382
Protocol IDs
A031702
A031702
NCI-2019-01266
Treatment Sites (4)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.